You can buy or sell Omeros and other stocks, options, ETFs, and crypto commission-free!
Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. Read More It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
52 Week High
52 Week Low
Yahoo FinanceMar 19
Omeros Corporation Announces Upcoming Educational Event at the Annual Meeting of the European Society of Blood and Marrow Transplantation
SEATTLE--(BUSINESS WIRE)-- --Session Will Focus on Diagnosis of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy-- Omeros Corporation (OMER) today announced an upcoming educational event at the 2019 Annual Meeting of the European Society of Blood and Marrow Transplantation to be held in Frankfurt, Germany on March 24-27, 2019. Sponsored by Omeros, the educational session entitled “How Do I … Diagnose HSCT-TMA” will be held on Tuesday, March 26, at 2:00-3:30 PM local time. There is ...
Yahoo FinanceMar 13
What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades. Even though momentum is a popular stock ch...
Seeking AlphaMar 13
Omeros Rising: Prospects, Income, Expenses Spell Risk Overmatched By Opportunity
Omeros never has quite enough cash to satisfy any comfortable margin of safety. Omeros (OMER) is a clinical stage biotech that is in the midst of a pullback. I expect it to recover and will be watching for healthy returns once one of its Phase 3 candidates hauls in an FDA or EMA approval. In the meantime, Omeros presents a highly attractive speculative acquisition as I discuss below. Omeros' pipeline has significant near-to-midterm revenue potential. Omeros' lead compound (OMS721), as a generic recently ...
Expected May 9, Pre-Market